Payment overview · 2025
General Payments
$896.01
44 reported records · 16 companies
Healthcare provider profile · identity verified
Charles Patrick Cole, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MEADVILLE, PA · NPI 1316021751
Verified facts
What the public records show
CMS Open Payments records show Charles Patrick Cole, M.D. received $896.01 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulance by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $240.39 | 26.8% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $102.38 | 11.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $68.61 | 7.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.61 | 6.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $61.10 | 6.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.39 | 6.6% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.44 | 5.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.16 | 5.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.73 | 4.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.50 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.83 | 3.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.92 | 3.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.42 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.08 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.38 | 1.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.07 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $896.01 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $163.48 | 8 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $144.47 | 1 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $144.47 | 1 | 2025 |
Source payment records
|
|||||
| XEN GLAUCOMA TREATMENT SYSTEM Normalized: xen glaucoma treatment system |
Device | ABBVIE INC. | $144.47 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.39 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.39 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.39 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $50.44 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.16 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.73 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.26 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.83 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.92 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 75 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 81 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Dexamethasone | Dexamethasone | 315 | 159 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 298 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 77 |
| Omeprazole | Omeprazole | 272 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 61 |
| Baclofen | Baclofen | 232 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 67 |
| Gabapentin | Gabapentin | 186 | 48 |
| Metformin Hcl | Metformin Hcl | 186 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 53 |
| Famotidine | Famotidine | 170 | 54 |
| Bupropion Xl | Bupropion Hcl | 169 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 152 | 34 |
| Sucralfate | Sucralfate | 151 | 43 |
| Clonazepam | Clonazepam | 150 | 30 |
| Montelukast Sodium | Montelukast Sodium | 147 | 44 |
| Meloxicam | Meloxicam | 146 | 50 |
| Buspirone Hcl | Buspirone Hcl | 137 | 34 |
| Methylprednisolone | Methylprednisolone | 136 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 30 |
| Losartan Potassium | Losartan Potassium | 126 | 46 |
| Pregabalin | Pregabalin | 126 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 45 |
| Lisinopril | Lisinopril | 114 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 114 | 20 |
| Tramadol Hcl | Tramadol Hcl | 111 | 29 |
| Furosemide | Furosemide | 109 | 49 |
| Mupirocin | Mupirocin | 101 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 97 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 21 |
| Topiramate | Topiramate | 87 | 20 |
| Atenolol | Atenolol | 84 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 84 | 21 |
| Mounjaro | Tirzepatide | 81 | 14 |
| Simvastatin | Simvastatin | 80 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 60 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 60 |
| Potassium Chloride | Potassium Chloride | 76 | 25 |
| Sertraline Hcl | Sertraline Hcl | 76 | suppressed |
| Eliquis | Apixaban | 75 | 21 |
| Azithromycin | Azithromycin | 73 | 56 |
| Jardiance | Empagliflozin | 71 | 15 |
| Alprazolam | Alprazolam | 67 | suppressed |
| Synthroid | Levothyroxine Sodium | 67 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 15 |
| Allopurinol | Allopurinol | 64 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 11 |
| Trazodone Hcl | Trazodone Hcl | 63 | 15 |
| Colestipol Hcl | Colestipol Hcl | 61 | 19 |
| Ezetimibe | Ezetimibe | 58 | 22 |
| Metformin Hcl Er | Metformin Hcl | 57 | 13 |
| Methocarbamol | Methocarbamol | 56 | 23 |
| Trulicity | Dulaglutide | 56 | 12 |
| Glipizide Er | Glipizide | 55 | 20 |
| Chlorthalidone | Chlorthalidone | 53 | 15 |
| Fluconazole | Fluconazole | 53 | 38 |
| Mirtazapine | Mirtazapine | 52 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 49 | 16 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Lidocaine | Lidocaine | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 13 |
| Ondansetron Odt | Ondansetron | 46 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 44 | 20 |
| Lorazepam | Lorazepam | 44 | 14 |
| Valsartan | Valsartan | 44 | 12 |
| Linzess | Linaclotide | 43 | 12 |
| Torsemide | Torsemide | 43 | 17 |
| Xarelto | Rivaroxaban | 43 | 15 |
| Carvedilol | Carvedilol | 40 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Diazepam | Diazepam | 39 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 16 |
| Roflumilast | Roflumilast | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 15 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 15 |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Clotrimazole | Clotrimazole | 33 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 13 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 32 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 11 |
| Ozempic | Semaglutide | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | 16 |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 23 |
| Procrit | Epoetin Alfa | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Temazepam | Temazepam | 21 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 20 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | 14 |
| Nizatidine | Nizatidine | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Digoxin | Digoxin | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $896.01 · 44 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, DURYSTA, ELIQUIS, JARDIANCE, LINZESS, LUMIGAN, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REXULTI, TRELEGY ELLIPTA, TRINTELLIX, VOQUEZNA, VRAYLAR, Wegovy, XEN GLAUCOMA TREATMENT SYSTEM, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error